This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wolf Haldenstein Investigates Abraxis Bioscience, Inc. Proposed Acquisition

Attorney Advertising. The law firm of Wolf Haldenstein Adler Freeman & Herz LLP is investigating possible breaches of fiduciary duty and other possible violations of state law by members of the Board of Directors of Abraxis Bioscience, Inc. (“Abraxis” or the “Company”) [NASDAQ:ABII] arising out of the Company’s entry into a definitive merger agreement to be acquired by Celgene Corp. (“Celgene”).

On June 30, 2010, Abraxis announced it had executed a definitive merger agreement with Celgene, whereby Abraxis shareholders will receive $58.00 in cash and .2617 shares of Celgene common stock for each share of Abraxis they hold, for an implied total consideration of approximately $71.93 per Abraxis share. Abraxis shareholders will also receive one tradeable Contingent Value Right (CVR) per share, which entitles its holder to receive payments for future regulatory milestones and commercial royalties. Should the transaction be approved, it is expected to close in the fourth quarter of 2010.

At issue in the investigation is whether or not the Board of Directors of Abraxis sought to obtain the best possible consideration for all the shareholders of Abraxis. The investigation will in part focus on a new drug developed by Abraxis, named ABRAXANE, which in clinical trials has shown a very positive response rate in treating certain types of lung cancer. ABRAXANE has already been approved by U.S. regulators for treating metastatic breast cancer, and brought in $315 million in sales last year. The drug is expected to earn $1 billion by 2015 upon its approval to treat other cancers. In spite of this valuable drug, the Company’s Board of Directors is attempting to sell Abraxis at a premium of only 17.32%.

Wolf Haldenstein has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in U.S. federal and state courts. Please visit the Wolf Haldenstein website ( for more information about the firm.

If you own Abraxis common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $36.00 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs